Good read. They do say that the two treatments offer differing attacks. If the two were really similar why wouldn't they try to extend the 2 year agreement. After reading this I believe we are not hearing the whole story yet and cubist obviously thinks their drug has a future. To the person who said both were basically one trick ponies- cubist is approaching phase 3 with 2 products, has one on the market (in addition to the 2 year with dificid), and has a couple more in phase 1 and 2.